# REZLIDHIA (olutasidenib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/olutasidenib

> The FDA approved REZLIDHIA (olutasidenib), sponsored by RIGEL PHARMACEUTICALS INC (RIGL), on Dec 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | REZLIDHIA (olutasidenib) |
| Codes | FT2101 |
| Sponsor | RIGEL PHARMACEUTICALS INC (RIGL) https://sec-api.dev/companies/rigl/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### Dec 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-04, last confirmed 2025-11-04.
- SEC Form 10-Q (accession 0001104659-25-106268): "In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and we began the commercialization of REZLIDHIA and made it available to patients." https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010281): "In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and we began the commercialization of REZLIDHIA and made it available to patients." https://www.sec.gov/Archives/edgar/data/1034842/000155837025010281/rigl-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006493): "In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and we began the commercialization of REZLIDHIA and made it available to patients." https://www.sec.gov/Archives/edgar/data/1034842/000155837025006493/rigl-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002169): "In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and we began the commercialization of REZLIDHIA and made it available to patients." https://www.sec.gov/Archives/edgar/data/1034842/000155837025002169/rigl-20241231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/olutasidenib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REZLIDHIA (olutasidenib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/olutasidenib

```bibtex
@misc{secapidev_pdufa_olutasidenib_20261116,
  title        = {REZLIDHIA (olutasidenib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/olutasidenib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_olutasidenib_20261116","title":"REZLIDHIA (olutasidenib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/olutasidenib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
